Stegent Equity Advisors’s AbbVie ABBV Stock Holding History

Stegent Equity Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.69M	Sell	7,750 -3,179	-29%	-$705K	1.44%	23
2025 Q4	$2.5M	Buy	10,929 +7,400	+210%	+$1.69M	1.95%	11
2025 Q3	$817K	Sell	3,529 -4,471	-56%	-$910K	0.67%	47
2025 Q2	$1.48M	Buy	8,000 +3,538	+79%	+$658K	1.31%	26
2025 Q1	$935K	Buy	+4,462	New	+$867K	0.95%	33
2024 Q3	–	Sell	-1,917	Closed	-$329K	–	89
2024 Q2	$329K	Sell	1,917 -3,659	-66%	-$606K	0.34%	57
2024 Q1	$1.02M	Buy	5,576 +3,977	+249%	+$685K	1.03%	37
2023 Q4	$248K	Buy	+1,599	New	+$233K	0.29%	59

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Stegent Equity Advisors's ABBV Position: Q1 2026 in Review

Stegent Equity Advisors reduced its AbbVie (ABBV) stake by 29% in Q1 2026, selling an estimated $705K and leaving 7,750 shares worth $1.69M. The position accounts for 1.44% of the portfolio, ranked #23.

Stegent Equity Advisors first reported a position in ABBV in Q4 2023 and has held it in 8 quarters since. The position peaked at $2.5M in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Stegent Equity Advisors held 7,750 shares of AbbVie worth $1.69M as of Q1 2026.
Stegent Equity Advisors sold 3,179 AbbVie shares in Q1 2026, an estimated $705K.
AbbVie made up 1.44% of Stegent Equity Advisors's portfolio in Q1 2026, its #23 holding.
Stegent Equity Advisors first reported a position in AbbVie in Q4 2023 and has held it in 8 quarters since.
Stegent Equity Advisors's AbbVie position peaked at $2.5M in Q4 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Stegent Equity Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.